Lasa Supergenerics Ltd

Lasa Supergeneri Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Lasa Supergenerics Ltd

₹ 12.6 -4.70%
13 Jun - close price
lasalabs.com BSE: 540702 NSE: LASA
About

Incorporated in 2016, Lasa Supergenerics Ltd is in the business of manufacturing, trading, producing, processing, preparing, treating chemicals, API, Pharmaceuticals, drugs, etc.[1]

Key Points

Business Overview:[1]
LSL is a part of Lasa group which is a veterinary API manufacturing entity. It specialises in ‘catalyst chemistry’ and manufactures anthelmintic/ veterinary APIs with one of the largest production capabilities in India. It covers entire animal and human healthcare value chain—from discovery-to-delivery, in research, manufacturing and global marketing. Company has backward integrated its key molecules—from discovery research up to full-scale bulk production

Website BSE NSE - BE
  • Market Cap ₹ 62.8 Cr.
  • Current Price ₹ 12.6
  • High / Low ₹ 33.5 / 12.5
  • Stock P/E 69.0
  • Book Value ₹ 16.7
  • Dividend Yield 0.00 %
  • ROCE -1.00 %
  • ROE 1.01 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Stock is trading at 0.75 times its book value
  • Company is expected to give good quarter

Cons

  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of -3.16% over past five years.
  • Company has a low return on equity of -9.72% over last 3 years.
  • Company's cost of borrowing seems high

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Figures in Rs. Crores

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
51 29 34 32 35 31 24 27 23 31 39 33 39
40 37 34 34 31 27 23 26 27 29 39 33 36
Operating Profit 11 -8 -0 -2 4 4 1 1 -4 2 1 0 3
OPM % 21% -28% -1% -8% 12% 13% 4% 4% -17% 6% 2% 1% 9%
4 0 -2 1 -19 0 0 0 -9 0 2 9 -22
Interest 0 0 1 0 0 0 1 0 1 1 1 0 0
Depreciation 4 3 3 3 4 3 3 3 3 3 3 3 4
Profit before tax 11 -11 -7 -5 -19 1 -2 -2 -16 -2 -1 6 -22
Tax % -7% 8% -2% -4% -22% 581% -99% -30% -4% 47% 147% 7% -35%
12 -12 -7 -5 -15 -5 -0 -1 -15 -3 -3 5 -14
EPS in Rs 2.98 -2.97 -1.63 -1.21 -2.99 -0.99 -0.00 -0.29 -3.05 -0.54 -0.64 1.10 -2.85
Raw PDF

Profit & Loss

Figures in Rs. Crores

Mar 2016 1m Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
0 199 244 170 167 201 137 130 104 142
0 153 202 158 137 154 120 136 102 136
Operating Profit 0 46 41 11 30 47 16 -6 2 6
OPM % 23% 17% 7% 18% 24% 12% -5% 2% 4%
0 -24 3 0 0 0 -8 -18 -9 -11
Interest 0 12 11 8 8 2 0 4 2 3
Depreciation 0 8 18 19 17 16 15 13 11 12
Profit before tax 0 2 15 -16 5 30 -6 -42 -19 -19
Tax % -10% 19% -25% 23% 23% -13% -9% 14% -24%
0 2 12 -12 4 23 -5 -39 -22 -15
EPS in Rs 5.40 -5.26 0.89 5.60 -1.31 -7.71 -4.34 -2.95
Dividend Payout % 0% 0% 0% 0% 4% -24% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: -3%
3 Years: 1%
TTM: 37%
Compounded Profit Growth
10 Years: %
5 Years: -25%
3 Years: -28%
TTM: 106%
Stock Price CAGR
10 Years: %
5 Years: -19%
3 Years: -31%
1 Year: -46%
Return on Equity
10 Years: %
5 Years: -1%
3 Years: -10%
Last Year: 1%

Balance Sheet

Figures in Rs. Crores

Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 0.05 0.05 23 23 41 41 50 50 50 50
Reserves 0 75 94 82 101 118 108 68 47 34
0 116 107 85 48 19 20 22 22 2
0 37 63 69 42 29 31 24 32 16
Total Liabilities 0 228 287 258 232 208 209 164 151 102
0 119 170 162 152 143 137 119 110 68
CWIP 0 30 7 7 0 0 5 5 3 0
Investments 0 0 0 0 0 0 0 0 0 0
0 80 110 90 80 65 67 40 39 33
Total Assets 0 228 287 258 232 208 209 164 151 102

Cash Flows

Figures in Rs. Crores

Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
0 -3 40 41 14 41 9 -17 2 -3
0 0 -44 -7 -2 -4 -3 11 -0 8
0 0 4 -33 -10 -36 -0 -4 -2 -6
Net Cash Flow 0 -3 0 -0 2 1 6 -10 -0 -0

Ratios

Figures in Rs. Crores

Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 64 63 62 45 27 50 7 13 4
Inventory Days 93 90 90 101 56 46 48 92 84
Days Payable 71 102 170 130 41 68 32 68 35
Cash Conversion Cycle 87 51 -18 16 42 28 22 37 53
Working Capital Days 58 44 -2 31 35 12 45 34 43
ROCE % 42% 13% -4% 7% 17% 1% -12% -6% -1%

Shareholding Pattern

Numbers in percentages

1 Recently
Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
43.78% 43.78% 43.78% 53.65% 53.65% 53.65% 53.65% 53.65% 53.65% 53.65% 53.65% 53.65%
0.40% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.12% 0.00% 0.01% 0.00% 0.00%
55.82% 56.21% 56.21% 46.34% 46.34% 46.34% 46.33% 46.23% 46.34% 46.32% 46.35% 46.35%
No. of Shareholders 30,08729,69228,93628,81828,03127,77027,16127,61527,21727,96827,27227,188

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Concalls